Precigen Inc (PGEN)
Healthcare
Biotechnology
6.50 $
-1.2%
vs. previous close
Closing price · As of: 4. Aug 2026
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -8.1% | -20.8% | -10.7% | -45.7% | +14.1% | +74.0% | -11.3% | -20.9% | +68.1% | -8.5% | -11.5% | |
| – | -12.0% | -26.1% | -27.9% | -52.1% | +45.5% | +196.7% | -17.4% | -25.8% | +106.5% | -11.1% | -11.8% | |
| – | -39.1% | -24.8% | +130.6% | -46.5% | +164.6% | +19.4% | -79.5% | +127.1% | +4.1% | +111.1% | -75.3% | |
| – | -16.6% | -14.8% | -28.8% | -56.4% | +46.6% | +242.0% | -18.0% | -25.5% | +102.7% | -19.2% | -42.5% | |
| – | -2.1% | -88.8% | -26.2% | -12.6% | -28.2% | +59.5% | -8.5% | -46.3% | +92.6% | +296.5% | +512.2% | |
| – | – | – | +0.0% | – | – | – | – | – | – | +213.2% | +53.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -0.2% | -27.9% | -0.2% | -6.2% | +0.0% | -23.2% | +0.0% | -20.4% | +0.0% | +0.0% | +0.0% | |
| – | -5.2% | +0.7% | -4.9% | -86.9% | -6.2% | -6.7% | -7.2% | -7.7% | -8.3% | -9.1% | -10.0% | |
| – | +4.1% | -24.3% | +16.2% | -20.7% | -6.3% | +279.9% | +33.8% | -2.9% | -6.7% | +4.9% | -12.8% | |
| – | +6.8% | -30.1% | +25.2% | -20.0% | -7.8% | +1.4% | +11.5% | -3.3% | +38.3% | +16.3% | -43.4% | |
| – | -15.6% | +0.2% | +9.7% | -3.7% | -22.1% | -3.2% | -2.9% | +0.2% | +20.8% | +1.2% | -6.0% | |
| – | -6.3% | -26.6% | +173.2% | +2.8% | -10.9% | -18.3% | -12.0% | +26.2% | +59.7% | +91.4% | -78.4% | |
| – | – | – | – | – | – | – | – | – | – | +0.3% | +0.4% | |
| – | -11.1% | -19.8% | -18.1% | -55.5% | +28.3% | -30.5% | -136.5% | – | – | -50.1% | -3.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.2% | +0.2% | +0.1% | +1.3% | +9.3% | +6.2% | +0.3% | +0.9% | +0.0% | +5.6% | +0.0% |
Data as of: August 4, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.